The panelists agreed that, in patients with confirmed glioblastoma (IDH-wildtype) or grade 4 IDH-mutated astrocytoma, MGMT promoter methylation status should be tested to inform prognosis and predict response to temozolomide chemotherapy. This evidence concerns the gene IDH1 and glioblastoma.